Snapshot from Sep 12, 2026 at 07:00 UTC. For live data and tracking: View Live
Business equity financing

Airway Therapeutics closes $50M equity round

Analysis based on 7 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026

Sentiment
30
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The $50 million equity round strengthens Airway Therapeutics' balance sheet, enabling it to advance its lead candidate through late-stage clinical development without immediate liquidity concerns. This financing signals investor confidence in the company's pipeline and may positively influence its valuation in future funding rounds.

Biotechnology Pharmaceuticals

Airway Therapeutics, a late-stage clinical biopharmaceutical company, announced the closing of a $50 million equity round to support the continued development of zelpultide alfa, its novel recombinant human surfactant protein D (rhSP-D) for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants. The round consists of $26 million previously raised through a SAFE financing and $24 million through a Series E-2 round. Approximately 94% of existing investors participated, including Cincinnati Children's and a syndicate of large family offices. Proceeds will fund the ongoing Phase 2b/3 clinical trial, CMC and analytical activities, and BLA readiness. The interim analysis completing the Phase 2b portion is expected by the end of Q2 2027.

priv
Airway Therapeutics is the company raising $50 million to fund its lead candidate zelpultide alfa. The financing strengthens its financial position and supports ongoing Phase 2b/3 trial, enhancing its ability to reach key milestones.
Importance 100.0 Sentiment 70.0
priv
Cincinnati Children's participated as an investor in the Series E-2 round, demonstrating support for the development of zelpultide alfa. Its involvement adds credibility and financial backing to the company.
Importance 30.0 Sentiment 40.0
per
Marc Salzberg, Chairman and CEO of Airway Therapeutics, expressed confidence in the round and the company's progress. His leadership is central to the company's strategy and execution.
Importance 20.0 Sentiment 30.0
per
Alan S. Wolk, CFO and COO, highlighted the financial solidification and efficient use of proceeds. His role is key in managing the company's finances and operations.
Importance 15.0 Sentiment 30.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.